PGEN

Precigen Inc

6.05

Oct 27 • 7:01 AM ET +0.01 (0.17%)

Healthcare Biotechnology USA Mid NASD

Peers: INO KRYS CGON CADL PDSB URGN ABEO IOVA RGNX VCEL

| Held by: VTI XBI IWM VXF IWO VTWO IBB GRNJ SCHA FYC

Index	RUT
Market Cap	2.17B
Enterprise Value	2.23B
Income	-336.70M
Sales	85.72M
Book/sh	0.12
Cash/sh	0.11
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	160
IPO	Aug 08, 2013

P/E	-
Forward P/E	9.71
PEG	-
P/S	25.27
P/B	49.70
P/C	56.69
P/FCF	-
EV/EBITDA	-
EV/Sales	25.97
Quick Ratio	3.89
Current Ratio	4.58
Debt/Eq	2.26
LT Debt/Eq	2.23
Option/Short	Yes / Yes

EPS (ttm)	-1.10
EPS next Y	0.62
EPS next Q	0.06
EPS this Y	111.78%
EPS next Y	286.08%
EPS next 5Y	-
EPS past 3/5Y	-60.61% -6.02%
Sales past 3/5Y	-28.87% -37.70%
EPS Y/Y TTM	-154.83%
Sales Y/Y TTM	1875.05%
EPS Q/Q	153.95%
Sales Q/Q	6322.66%
Earnings	Aug 04 AMC
EPS/Sales Surpr.	513.22% 96.47%

Insider Own	54.13%
Insider Trans	-0.68%
Inst Own	39.45%
Inst Trans	2.53%
ROA	-115.88%
ROE	-837.08%
ROIC	-111.95%
Gross Margin	89.19%
Oper. Margin	-46.08%
Profit Margin	-392.81%
SMA20	-16.20%
SMA50	-16.54%
SMA200	15.59%
Trades

Shs Outstand	358.01M
Shs Float	164.24M
Short Float	28.25%
Short Ratio	8.93
Short Interest	46.39M
52W High	8.98 -32.63%
52W Low	3.04 99.01%
Volatility	5.26% 6.00%
ATR (14)	0.38
RSI (14)	33.28
Beta	1.00
Rel Volume	0.01
Avg Volume	5.20M
Volume	3,242

Perf Week	-11.42%
Perf Month	-22.54%
Perf Quarter	11.01%
Perf Half Y	50.50%
Perf YTD	44.74%
Perf Year	40.70%
Perf 3Y	499.01%
Perf 5Y	34.44%
Perf 10Y	-76.60%
Recom	1.50
Target Price	13.67
Prev Close	6.04
Price	6.05
Change %	0.17%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-25-26	Initiated	B. Riley Securities	Buy	$12
Aug-15-25	Upgrade	JP Morgan	Underweight → Neutral
Mar-22-24	Downgrade	JP Morgan	Neutral → Underweight
May-23-23	Initiated	JP Morgan	Neutral
Nov-18-22	Initiated	Cantor Fitzgerald	Overweight	$7
Feb-25-21	Initiated	Stifel	Buy	$13
Feb-22-21	Initiated	Wells Fargo	Overweight	$14
Feb-18-21	Initiated	B. Riley Securities	Buy	$10
May-08-20	Initiated	H.C. Wainwright	Buy	$5

Sep-25-26 02:37PM	MRNA, PGEN Stocks Hit Multi-Year Highs Whats Driving The Momentum Today? (Stocktwits)
Sep-21-26 07:00AM	Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform (PR Newswire)
Aug-25-26 07:00AM	Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers (ACCESSWIRE)
Aug-05-26 01:04AM	Precigen Inc (PGEN) (Q2 2026) Earnings Call Highlights: Revenue Surges 145% and Net Profit Achieved (GuruFocus.com) +5.51%
Aug-04-26 04:01PM	Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth (PR Newswire)
08:00AM	Loading…
Jul-21-26 08:00AM	Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4 (PR Newswire) +8.28%
Jun-15-26 06:40AM	Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging (ACCESSWIRE) +7.87%
Jun-11-26 08:00AM	Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices (PR Newswire) +16.45%
May-30-26 02:30PM	Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years (PR Newswire)
May-27-26 07:00AM	Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States (PR Newswire)
May-26-26 08:05AM	Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference (PR Newswire)
May-14-26 01:02AM	Precigen Inc (PGEN) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid Operational ... (GuruFocus.com) +10.84%
May-13-26 04:05PM	Precigen Reports First Quarter 2026 Financial Results and Business Updates (PR Newswire)
May-07-26 04:05PM	Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13 (PR Newswire) -5.68%
Apr-07-26 07:00AM	Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million (ACCESSWIRE)
08:30AM	Loading…
Mar-30-26 08:30AM	Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31 (PR Newswire) -11.44%
Mar-25-26 11:02PM	Precigen Inc (PGEN) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Expansion ... (GuruFocus.com) +25.48%
04:05PM	Precigen Reports Full Year 2025 Financial Results and Business Updates (PR Newswire)
Mar-11-26 04:05PM	Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25 (PR Newswire)
Mar-05-26 08:50AM	CorMedix (CRMD) Lags Q4 Earnings Estimates (Zacks) -5.07%
08:40AM	Precigen (PGEN) Surged Following the Early Approval of Papziemos (Insider Monkey)
Feb-13-26 07:14AM	Precigen, Inc. (PGEN) Builds Commercial Stage With Global Regulatory Support (Insider Monkey)
Jan-20-26 08:05AM	New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis (PR Newswire)
Jan-12-26 08:00AM	Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire) -9.91%
Jan-05-26 04:05PM	Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire) +8.85%
Nov-14-25 12:01AM	Precigen Inc (PGEN) Q3 2025 Earnings Call Highlights: FDA Approval and U.S. ... (GuruFocus.com) +25.65%
Nov-13-25 04:05PM	Precigen Reports Third Quarter 2025 Financial Results and Business Updates (PR Newswire)
Nov-06-25 04:30PM	Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13 (PR Newswire)
Oct-26-25 06:05AM	Precigen Reports Positive Long-Term Follow-Up Data for FDA-Approved RRP Therapy, PAPZIMEOS (Insider Monkey)
Oct-13-25 07:00AM	Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis (PR Newswire)
07:23PM	Loading…
Sep-23-25 07:23PM	Precigen, Inc. (PGEN) Secures $125M to Accelerate PAPZIMEOS Commercialization (Insider Monkey)
Sep-20-25 02:43AM	Precigen, Inc. (PGEN) Bolsters Financial Standing to Enhance PAPZIMEOS Commercialization (Insider Monkey)
Sep-15-25 08:17AM	Precigen Signs a Credit Facility Agreement Worth $125 Million to Support PAPZIMEOS (Insider Monkey) -5.28%
Sep-12-25 03:41AM	4 years from clinic to approval Precigens unprecedented FDA nod and what comes next (Pharma Voice) -8.45%
Sep-11-25 03:31AM	Precigen's (PGEN) Papzimeos Push Sparks Multibagger Ascent, Boosted by Analyst Optimism (Insider Monkey)
Sep-07-25 08:23AM	These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts (Motley Fool)
Sep-03-25 07:00AM	Precigen Announces Up to $125 Million Non-Dilutive Financing (PR Newswire)
Sep-02-25 12:57AM	Cantor Fitzgerald Reaffirms Overweight Rating on Precigen (PGEN) (Insider Monkey) +5.54%
Aug-28-25 10:00AM	INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug (Zacks)
Aug-26-25 08:39AM	Citizens JMP Raises PT on Precigen from $6 to $8, Keeps Outperform Rating (Insider Monkey) +7.04%
Aug-25-25 11:56PM	H.C. Wainwright Remains Bullish on Precigen (PGEN) (Insider Monkey)
11:04AM	PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug (Zacks)
10:30AM	BC-Most Active Stocks (Associated Press Finance)
08:05AM	Precigen to Participate in Upcoming Virtual Fireside Chats Hosted by Cantor and H.C. Wainwright (PR Newswire)
Aug-20-25 12:22AM	Precigen (PGEN) Secures FDA Approval for Papillomatosis Treatment (Insider Monkey)
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
07:42AM	FDA approves Papzimeos as first therapy for HPV-caused airway disease (Pharmaceutical Technology)
Aug-15-25 10:45AM	Hope Realized: FDA Approves Papzimeos for Adults with Recurrent Respiratory Papillomatosis (RRP) (Business Wire) +58.92%
10:30AM	BC-Most Active Stocks (Associated Press Finance)
07:20AM	Precigen wins immunotherapy approval; Pfizer sickle cell drug fails trial (BioPharma Dive)
07:00AM	Precigen Announces Full FDA Approval of PAPZIMEOS (zopapogene imadenovec-drba), the First and Only Approved Therapy for the Treatment of Adults with Recurrent Respiratory Papillomatosis (PR Newswire)
May-14-25 04:05PM	Precigen Reports First Quarter 2025 Financial Results and Business Updates (PR Newswire) -5.19%
Apr-22-25 12:00PM	Patient Capital Management Q1 2025 Investment Review (Seeking Alpha) +11.68%
Apr-16-25 08:05AM	Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th (PR Newswire)
Mar-27-25 10:19AM	Is Precigen (PGEN) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-21-25 06:23PM	Precigen Inc (PGEN) Q4 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Mar-19-25 07:47PM	Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript (SeekingAlpha) +7.19%
06:25PM	Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Precigen Reports Full Year 2024 Financial Results and Business Updates (PR Newswire)
Mar-13-25 08:05AM	Precigen to Announce Full Year 2024 Financial Results and Provide Business Updates on March 19th (PR Newswire)
Mar-01-25 05:27PM	Why Precigen, Inc. (PGEN) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-25-25 08:05AM	FDA Grants Priority Review to Precigen's BLA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis with PDUFA Target Action Date Set for August 27, 2025 (PR Newswire)
Jan-13-25 07:00AM	Precigen to Present Plans for Realizing Commercial Vision for PRGN-2012 at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire) -8.94%
Jan-09-25 08:30AM	Precigen to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-30-24 07:00AM	Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (PR Newswire) +28.47%
Dec-27-24 09:00AM	Precigen Announces $79.0 Million Private Placement Offering of Convertible Preferred Stock (PR Newswire)
Nov-14-24 04:30PM	Precigen Reports Third Quarter 2024 Financial Results and Business Updates (PR Newswire) -7.11%
Nov-12-24 04:05PM	Precigen to Participate in the Stifel 2024 Healthcare Conference (PR Newswire) -5.04%
Sep-16-24 04:30PM	Precigen to Participate in the 2024 Cantor Global Healthcare Conference (PR Newswire)
Aug-14-24 04:05PM	Precigen Reports Second Quarter and First Half 2024 Financial Results and Business Updates (PR Newswire)
01:54PM	Hedge Fund and Insider Trading News: Nelson Peltz, Jana Partners, Whitebox Advisors, Caxton Associates LP, Altium Capital, Soros Fund Management, Elliott Investment Management, Balyasny Asset Management, Precigen Inc (PGEN), Vulcan Materials Company (VMC), and More (Insider Monkey)
Aug-09-24 08:00AM	Precigen to Announce Second Quarter and First Half 2024 Financial Results on August 14th (PR Newswire) -13.39%
Aug-07-24 09:30PM	Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock (PR Newswire) -12.59% +7.63%
Aug-06-24 04:04PM	Precigen Announces Proposed $30 Million Public Offering of Common Stock (PR Newswire)
04:01PM	Precigen Strategically Prioritizes Portfolio to Focus on First Potential Gene Therapy Launch (PR Newswire)
Jul-23-24 08:01AM	Precigen Appoints Phil Tennant as Chief Commercial Officer to Spearhead First Potential Gene Therapy Launch (PR Newswire)
Jun-03-24 09:30AM	Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response (PR Newswire) +11.43%
May-23-24 05:00PM	Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting (PR Newswire)
May-14-24 05:20PM	Precigen, Inc. (PGEN) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +5.11%
04:05PM	Precigen Reports First Quarter 2024 Financial Results and Business Updates (PR Newswire)
08:21AM	Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 04:05PM	Precigen to Announce First Quarter 2024 Financial Results on May 14th and Host a Conference Call on June 3rd following the Late-breaking Oral Presentation for PRGN-2012 at the 2024 ASCO Annual Meeting (PR Newswire)
Apr-24-24 10:20AM	Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting (PR Newswire)
09:00AM	Actym Therapeutics Appoints Thomas Smart as CEO (PR Newswire)
Mar-28-24 04:05PM	Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th (PR Newswire)
Mar-27-24 08:20AM	Analysts on Wall Street Lower Ratings for These 10 Stocks (Insider Monkey)
Mar-20-24 10:07AM	Precigen, Inc. (NASDAQ:PGEN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-19-24 08:53PM	PGEN Stock Earnings: Precigen Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
05:31PM	Precigen Inc (PGEN) Reports Full Year 2023 Financial Results (GuruFocus.com)
04:05PM	Precigen Reports Full Year 2023 Financial Results and Business Updates (PR Newswire)
Mar-12-24 04:05PM	Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis (PR Newswire)
Mar-05-24 04:05PM	Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th (PR Newswire)
Feb-06-24 04:05PM	Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference (PR Newswire)
Jan-16-24 08:05AM	Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission (PR Newswire)
Jan-08-24 08:30AM	Precigen Highlights Pipeline Updates to be Presented at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire) +8.53%
Jan-02-24 12:40PM	Hedge Fund and Insider Trading News: David Einhorn, Bill Ackman, D. E. Shaw, Steve Cohen, Rob Citrone, Saba Capital, HighPeak Energy, Inc (HPK), Precigen Inc (PGEN), and More (Insider Monkey) +5.22%
Dec-18-23 04:05PM	Precigen to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire) -5.74%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Thomasian Harry Jr.	Chief Financial Officer	Sep 23 '26	Option Exercise	2.81	53,665	150,714	311,914	Sep 24 04:19 PM
KINDLER JEFFREY B	Director	Aug 26 '26	Sale	7.44	185,000	1,376,400	17,100	Aug 28 08:39 PM
Jeffrey Kindler	Director	Aug 26 '26	Proposed Sale	7.42	185,000	1,372,700		Aug 26 04:43 PM
AGEE NANCY H	Director	Aug 21 '26	Buy	7.23	3,411	24,662	309,187	Aug 25 05:30 PM
Shah Rutul R	Chief Operating Officer	Aug 21 '26	Option Exercise	2.33	34,658	80,753	499,670	Aug 25 05:27 PM
Shah Rutul R	Chief Operating Officer	Aug 25 '26	Option Exercise	2.33	15,342	35,747	484,207	Aug 25 05:27 PM
Shah Rutul R	Chief Operating Officer	Aug 21 '26	Sale	7.50	34,658	259,935	465,012	Aug 25 05:27 PM
Shah Rutul R	Chief Operating Officer	Aug 25 '26	Sale	7.50	15,342	115,065	468,865	Aug 25 05:27 PM
Tennant Phil	Chief Commercial Officer	Aug 25 '26	Option Exercise	1.61	79,166	127,457	221,158	Aug 25 05:25 PM
Tennant Phil	Chief Commercial Officer	Aug 25 '26	Sale	7.50	79,166	593,745	141,992	Aug 25 05:25 PM
Shah Rutul R	Officer	Aug 25 '26	Proposed Sale	7.50	15,342	115,065		Aug 25 02:01 PM
Tennant Phil	Officer	Aug 25 '26	Proposed Sale	7.50	79,166	593,745		Aug 25 01:53 PM
Shah Rutul R	Officer	Aug 21 '26	Proposed Sale	7.50	34,658	259,935		Aug 21 04:31 PM
Shah Rutul R	Chief Operating Officer	Aug 06 '26	Sale	6.86	32,739	224,590	465,012	Aug 07 05:04 PM
Shah Rutul R	Officer	Aug 06 '26	Proposed Sale	6.86	32,739	224,590		Aug 06 01:17 PM
Shah Rutul R	Chief Operating Officer	Aug 03 '26	Option Exercise	2.33	33,772	78,689	531,523	Aug 03 06:12 PM
Shah Rutul R	Chief Operating Officer	Aug 03 '26	Sale	6.50	33,772	219,518	497,751	Aug 03 06:12 PM
Shah Rutul R	Officer	Aug 03 '26	Proposed Sale	6.50	33,772	219,518		Aug 03 03:21 PM
Thomasian Harry Jr.	Chief Financial Officer	Jul 31 '26	Sale	6.06	100,000	606,000	254,535	Jul 31 04:26 PM
Thomasian Harry Jr.	Officer	Jul 31 '26	Proposed Sale	6.06	100,000	605,610		Jul 31 11:12 AM
Thomasian Harry Jr.	Chief Financial Officer	Jul 01 '26	Sale	5.53	171,429	948,002	354,535	Jul 01 06:22 PM
Thomasian Harry Jr.	Chief Financial Officer	Jun 29 '26	Sale	5.78	28,571	165,140	525,964	Jul 01 06:22 PM
Shah Rutul R	Chief Operating Officer	Jun 29 '26	Option Exercise	2.33	42,924	100,013	540,675	Jul 01 06:21 PM
Shah Rutul R	Chief Operating Officer	Jun 29 '26	Sale	5.85	42,924	251,105	497,751	Jul 01 06:21 PM
Sabzevari Helen	President and CEO	Jun 29 '26	Option Exercise	2.33	346,836	808,128	4,115,708	Jul 01 06:19 PM
Sabzevari Helen	President and CEO	Jun 29 '26	Sale	5.89	346,836	2,042,864	3,768,872	Jul 01 06:19 PM
Thomasian Harry Jr.	Officer	Jul 01 '26	Proposed Sale	5.53	171,429	948,544		Jul 01 12:20 PM
Sabzevari Helen	Officer	Jun 29 '26	Proposed Sale	5.90	346,836	2,044,627		Jun 29 04:14 PM
Shah Rutul R	Officer	Jun 29 '26	Proposed Sale	5.85	42,924	251,105		Jun 29 11:30 AM
Thomasian Harry Jr.	Officer	Jun 29 '26	Proposed Sale	5.78	28,571	165,197		Jun 29 10:58 AM
Thomasian Harry Jr.	Chief Financial Officer	May 28 '26	Sale	4.36	41,884	182,614	554,535	Jun 01 04:29 PM
Tennant Phil	Chief Commercial Officer	May 28 '26	Sale	4.36	30,272	131,986	139,369	Jun 01 04:28 PM
Shah Rutul R	Chief Operating Officer	May 28 '26	Sale	4.36	42,703	186,185	497,751	Jun 01 04:27 PM
Lehr Donald P.	Chief Legal Officer	May 28 '26	Sale	4.36	29,131	127,011	755,461	Jun 01 04:26 PM
Sabzevari Helen	President and CEO	May 28 '26	Sale	4.36	119,250	519,930	3,768,872	Jun 01 04:25 PM
KIRK RANDAL J	Director	Mar 30 '26	Sale	3.30	4,772,781	15,750,177	302,213	Mar 31 04:10 PM
Randal J. Kirk	Director	Mar 30 '26	Proposed Sale	3.67	4,772,781	17,516,106		Mar 30 05:33 PM
KIRK RANDAL J	Director	Mar 13 '26	Option Exercise	0.00	143,678	0	81,781,816	Mar 16 05:29 PM
KIRK RANDAL J	Director	Dec 22 '25	Sale	4.18	1,900,036	7,942,150	341,189	Dec 22 08:48 PM
Randal J. Kirk	Director	Dec 22 '25	Proposed Sale	4.32	1,900,036	8,208,156		Dec 22 08:19 PM
KINDLER JEFFREY B	Director	Dec 12 '25	Sale	3.63	235,467	855,899	110,603	Dec 16 04:16 PM
Jeffrey Kindler	Director	Dec 12 '25	Proposed Sale	3.69	235,467	868,873		Dec 12 06:27 PM
KIRK RANDAL J	Director	Nov 19 '25	Sale	4.47	1,086,153	4,855,104	7,434,384	Nov 21 07:54 PM
KIRK RANDAL J	Director	Nov 20 '25	Sale	4.08	942,832	3,846,755	6,491,552	Nov 21 07:54 PM
KIRK RANDAL J	Director	Nov 21 '25	Sale	3.83	937,308	3,589,890	5,554,244	Nov 21 07:54 PM
KIRK RANDAL J	Director	Nov 20 '25	Proposed Sale	4.08	942,832	3,843,885		Nov 20 05:33 PM
KIRK RANDAL J	Director	Nov 19 '25	Proposed Sale	4.22	1,086,153	4,583,565		Nov 19 05:23 PM

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Executive ChairmanMr. Randal J. Kirk J.D.

Ph.D.Dr. Helen Sabzevari MPH

Chief Financial OfficerMr. Harry Thomasian Jr.

Chief Operating OfficerMr. Rutul R. Shah

Ph.D.Mr. Donald P. Lehr J.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PGEN

Precigen Inc

Upgrade your Finviz experience